GLP-1 receptor agonists tied to reduced acute asthma exacerbations in teens with overweight, obesity

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in adolescents with overweight or obesity, according to a research letter published online Dec. 29 in JAMA Network Open.
GLP-1 Market Trends and Global Forecasts 2025-2035: 150+ Candidates Intended for the Treatment of Multiple Indications, are Currently Either Approved or Being Investigated – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “GLP-1 Market: Industry Trends and Global Forecasts, Till 2035” report has been added to ResearchAndMarkets.com’s offering. The global GLP-1 market is estimated to grow from USD 62.2 billion in the current year to USD 157.5 billion by 2035, at a CAGR of 9.7% during the forecast period, till 2035. The efficacy of GLP-1 […]
Weight loss drugs are effective, but can healthcare systems afford them?

The use of glucagon-like peptide-1 (GLP-1) receptor agonist drugs for weight loss is increasing rapidly, with an estimated one in 50 adults in the UK using these treatments to help manage their weight.1 These drugs have been licensed based on trials that show a weight reduction of 15-20%, along with improvements in obesity related comorbidities.23 […]
I lost 8st on weight-loss jabs – but I am devastated by the aftermath

New data published in the British Medical Journal suggests overweight people shed large amounts when they take weight-loss drugs, but once they quit they regain it within 20 months of stopping the injections – four times faster than traditional dieters. “People buying these need to be aware of the risk of fast weight regain when […]
Novo Nordisk quietly loses key Washington insider amid pricing war

Novo Nordisk is trying to get back on track in the U.S., but it just lost an important worker in Washington. An internal memo said that Jennifer Duck, who was in charge of U.S. public affairs for Novo Nordisk, left the business on Jan. 5, Reuters reported. The developer of Wegovy and Ozempic is trying […]
Former GLP-1 users regain lost weight after about 18 months, study says

Those quitting Ozempic, Wegovy and other drugs regained weight four times faster than those using just diet and exercise, still key components in weight maintenance.
ChatGPT wants to reshape $4.9 trillion industry next

The U.S. poured $4.9 trillion into health care in 2023, equal to roughly 17.6% of GDP, federal data show. What jumps out from that number is not just the size, but how much of it is tied up in confusion, bureaucracy, and fragmentation that ordinary people feel every time they try to book an appointment […]
Shocking number of Americans would rather ditch social media than GLP-1 drugs: survey

The poll of 2,000 US adults found nearly a quarter currently use GLP-1s or have used them within the past five years.
Big push for small appetites: UK grocers dish up meals for GLP-1 users

The opening days of 2026 have seen a clutch of UK retailers roll out products with an eye on the rising number of people using GLP-1 weight-loss drugs. The post Big push for small appetites: UK grocers dish up meals for GLP-1 users appeared first on Just Food.
Cal-Maine Foods, Inc. (NASDAQ:CALM) Q2 2026 Earnings Call Transcript

Cal-Maine Foods, Inc. (NASDAQ:CALM) Q2 2026 Earnings Call Transcript January 7, 2026 Cal-Maine Foods, Inc. beats earnings expectations. Reported EPS is $2.13, expectations were $1.75. Operator: Good morning, everyone, and welcome to the Cal-Maine Foods Second Quarter Fiscal 2026 Earnings Conference Call. All participants are in a listen-only mode. After today’s prepared remarks, there will […]